Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026
Business Wire•19/10/2026•08:00 ET
0
Key Highlights
- ➤28 presentations, including two oral, scheduled at IDWeek 2026
- ➤Bixlenvo analyses assess HIV treatment outcomes with comorbidities and renal impairment
- ➤Yeztugo real-world adoption study covers nine months after U.S. approval
- ➤GS-1179 Phase 1b final results address efficacy, safety and tolerability
- ➤ACCELERATE study evaluates rapid Biktarvy ART restart after care interruptions
Expert Statements
Jared Baeten, Senior Vice President, Clinical Development, Virology Therapeutic Area Head, Gilead Sciences
“We remain committed to advancing options for people affected by HIV and other serious diseases, as evidenced by the breadth of our research and antiviral pipeline. These findings span clinical research and real-world evidence, deepening our understanding of evolving needs and informing innovations that have the potential to make a meaningful difference for the communities we serve.”
Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026
– Analyses of Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg) Examine Outcomes in People with HIV and Selected Comorbidities or Renal Impairment –
Get started
Create a free account to read the full story.